IMPAQ was selected by the Centers for Disease Control and Prevention (CDC) to produce precise estimates of the prevalence of mental health conditions and mental health utilization among cancer survivors using a statistical analysis performed on a large number of claims. The use of claims data will allow IMPAQ to estimate the prevalence of mental health conditions and mental health utilization among cancer survivors on relatively small subgroups such as particular demographics or individuals with a certain type of cancer, which is not possible with survey data.
This research study will be an important addition to the CDC’s research portfolio and has the intention of being widely disseminated through peer-reviewed journals and other venues. The CDC and other Federal agencies can use the results of this study to more effectively understand and appropriately target mental health resources to the cancer survivors most in need.
IMPAQ is partnering with IBM Watson Health to receive a custom sample of MarketScan data. We are also using a variety of statistical and regression models to produce accurate results that provide answers to the CDC’s research questions.
IMPAQ’s vast experience performing complex statistical and regression modeling and analyses of a variety of public and private claims data sets positions us to successfully provide the CDC with accurate and timely results that will be translated into meaningful, real-world impacts.